Funded under Horizon Europe’s Innovative Health Initiative (HORIZON-JU-IHI-2022-02-01) and running from 2023 to 2028, the iCARE4CVD project aims to improve patient care across the board, starting from those at risk of developing cardiovascular disease to those with advanced heart failure. Thomas More University of Applied Sciences plays an important role in the project focusing data analysis and AI modeling as well as on the implementation of Patient-Reported Outcome Measures and Patient-Reported Experience Measures. Find out more in the full article.

Funded under Horizon Europe (HORIZON-HLTH-2024-CARE-14-01), running from 2025 to 2029, the THERESA PCP aims to launch a pre-commercial procurement process (PCP) based on the development of an environmentally sustainable on-site system to decontaminate hospital wastewater. Ziekenhuis aan de Stroom (ZAS) plays an important role in the project by contributing real-world insights from a large and diverse hospital network. Read more about the project in this testimonial.

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.